Prulifloxacin Tablets

The drug targets bacterial DNA and inhibits the function of DNA topoisomerase II and IV, preventing bacterial DNA from forming supercoils and causing irreversible damage to chromosomes, which results in bacterial cells being unable to divide and reproduce, thus producing an antibacterial effect. This effect is generally highly selective for bacteria and safe for the human body.

Prulifloxacin. Chemical name: (plusmn;)-6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-1-piperazinyl]-4-oxo-4-hydrogen-[1,3]thiazine[3,2-a]quinoline-3-carboxylic acid.

This product is light yellow tablet.

It is used to treat the following infections caused by Staphylococcus aureus, gonococci, pneumococci, enterococci, Moraxella, Escherichia coli, Shigella, Salmonella (except typhoid and paratyphoid bacteria), citric acid bacteria, Klebsiella pneumoniae, Serratia, Proteus, Vibrio cholerae, Pseudomonas aeruginosa, and Streptococcus aureus that are sensitive to prulifloxacin: 1. Superficial skin infections (acute superficial folliculitis, infectious impotence), deep skin infections (cellulitis, erysipelas, furunculosis, furunculosis, carbuncle, suppurative perionychia), chronic pyoderma (infected sebaceous cysts, suppuration, etc.).

This product belongs to the quinolone antibiotics. It inhibits the activity of bacterial DNA topoisomerase II and IV, inhibits bacterial DNA synthesis, and completes the bactericidal effect. It is different from the traditional bactericidal mode and does not have the drug resistance phenomenon of other antibiotics. This drug has a broad antibacterial spectrum and has significant therapeutic effects on both Gram-negative and Gram-positive bacteria. It is particularly sensitive to Pseudomonas aeruginosa, and its antibacterial power exceeds that of other oxazolidinones and other currently marketed antibiotics.

Eosinopenia and elevated liver GPT were mild.

1. Patients who are allergic to this product or quinolone drugs are prohibited from using this product. 2. Pregnant women, lactating women and patients under 18 years old are prohibited from using this product.

Precautions for children: Do not use this product because its safety has not been established for low-birth-weight infants, newborns, nursing infants, infants and children. Precautions for pregnancy and lactation: The safety of this product for pregnant and lactating women has not been established. Lactating women should stop breastfeeding when taking this product. Precautions for the elderly: The half-life of this product is prolonged after the elderly take it.

1. Pharmacological action This product has a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, and particularly exhibits strong antibacterial activity against Gram-negative bacteria such as Pseudomonas aeruginosa and Enterobacter. Compared with norfloxacin, ofloxacin, levofloxacin, ciprofloxacin, tosufloxacin, fleroxacin, sparfloxacin, etc., the antibacterial activity of this product in vitro tests shows that it is equally superior or exceeds that of norfloxacin, ofloxacin, levofloxacin, ciprofloxacin, tosufloxacin, fleroxacin, sparfloxacin, etc. In particular, it has the strongest antibacterial activity against intestinal flora with MIC90 (μg/ml) of Escherichia coli (0.1), Citrobacter separate (0.1), Enterobacter aerogenes (0.2), Proteus mirabilis (≤0.05), Proteus vulgaris (≤0.05), and Proteus morganii (0.39). The MIC90 for Pseudomonas aeruginosa is 0.39μg/ml, far exceeding that of the other floxacins mentioned above.

seal.

0.1g (calculated as C16H16FN3O3S)

24 months

Zhejiang Jingxin Pharmaceutical Co., Ltd.

• Founded in:

  1999-02-13

• Address:

  No. 800, Xinchang Avenue East Road, Yulin Street, Xinchang County, Zhejiang Province

• Tax NO.:

  91330000704503984N

• Registered Funds:

  861.02914 million yuan

• Website:

  Log in to view

• Email:

  Log in to view